In a research report issued Friday, BTIG analyst Hartaj Singh reiterated a Neutral rating on Keryx Biopharmaceuticals (NASDAQ:KERX), after the company released its full …
Brean Capital’s healthcare analyst Jonathan Aschoff weighed in today with a few insights on Keryx Biopharmaceuticals (NASDAQ:KERX), as the company’s shares have reacted negatively to …
In a research report released Monday, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) with a $32 price …
In a research report sent to investors today, Cowen analyst Boris Peaker initiated coverage on Keryx Biopharmaceuticals (NASDAQ:KERX) with an Outperform rating and a $25 …
In a research report sent to investors today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) and raised his …
In a research report sent to investors today, H.C.
In a research report published Tuesday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) with a $26 price target, …
In a research note issued today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) with a $26 price target, as …
In a research report issued today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) with a $26 price target, …
Maxim Group analyst Jason Kolbert reaffirmed a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) with a $26 price target, which represents a potential upside of 53% …
